Squarepoint
TVTX icon

Squarepoint’s Travere Therapeutics TVTX Stock Holding History

Squarepoint’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,300
Closed -$435K – 5070
2025
Q1 		$435K Buy
+24,300
New +$493K ﹤0.01% 3432

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Squarepoint's TVTX Position: Q1 2026 in Review

Squarepoint reduced its Travere Therapeutics (TVTX) stake by 37% in Q1 2026, selling an estimated $3.57M and leaving 200,111 shares worth $5.95M. The position accounts for 0.01% of the portfolio, ranked #1373.

Squarepoint first reported a position in TVTX in Q4 2015 and has held it in 32 quarters since. The position peaked at $12.2M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Squarepoint held 200,111 shares of Travere Therapeutics worth $5.95M as of Q1 2026.
  • Squarepoint sold 119,547 Travere Therapeutics shares in Q1 2026, an estimated $3.57M.
  • Travere Therapeutics made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1373 holding.
  • Squarepoint first reported a position in Travere Therapeutics in Q4 2015 and has held it in 32 quarters since.
  • Squarepoint's Travere Therapeutics position peaked at $12.2M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.